1. Rebates for brand-name drugs in Part D substantially reduced the growth in spending from 2011 to 2015 Publication: [Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, September 2019 Subject(s): Drug Costs -- statistics & numerical dataDrug Costs -- trendsInsurance, Health, Reimbursement -- statistics & numerical dataInsurance, Health, Reimbursement -- trendsMedicare Part D -- economicsMedicare Part D -- statistics & numerical dataMedicare Part D -- trendsEconomics, Pharmaceutical -- statistics & numerical dataEconomics, Pharmaceutical -- trendsForecastingPrescription Drugs -- economicsHumansUnited States
